BackgroundTo explore the effect of mesenchymal stem cells isolated from menstrual blood (MB-MSCs) on epirubicin-induced damage to human ovarian granulosa cells (GCs) and its potential mechanisms.MethodsThe estradiol, progesterone, anti-Mullerian hormone, inhibin A, and inhibin B levels were determined using enzyme-linked immunosorbent assay. The proliferation of GCs was detected by Cell Counting Kit-8 assays. The cell cycle distribution was detected by propidiumiodide single staining. The apoptosis of GCs was determined using Annexin V and 7-AAD double staining. The differentially expressed genes of GCs were analyzed with Affymetrix Human Transcriptome Array 2.0 gene chip and verified with Western blot analysis.ResultsEpirubicin inhibited the secretion of estradiol, progesterone, anti-Mullerian hormone, inhibin A, and inhibin B and the proliferation of GCs; arrested these GCs in G2/M phase; and promoted the apoptosis of GCs. However, MB-MSCs repaired epirubicin-induced damage to GCs. Differentially expressed genes of GCs, Gadd45b, CyclinB1, and CDC2, were found by microarray and bioinformatics analysis. Western blot showed that epirubicin upregulated Gadd45b protein expression and downregulated CyclinB1 and CDC2 protein expression, while MB-MSCs downregulated Gadd45b protein expression and upregulated CyclinB1 and CDC2 protein expression.ConclusionsMB-MSCs repaired epirubicin-induced damage to GCs, which might be related to the inhibition of Gadd45b protein expression.

BACKGROUND: To investigate the therapeutic effects of menstrual blood derived mesenchymal stem cells (MB-MSCs) combined with Bushen Tiaochong recipe (BSTCR) on epirubicin induced premature ovarian failure (POF) in mice.; METHODS: Twenty-four female C57BL/6 mice of 6-8weeks were intraperitoneally injected with epirubicin to induce POF, and then they were randomized into 4 groups of 6 mice each and treated with PBS, MB-MSCs, BSTCR, and MB-MSCs combined with BSTCR, respectively. Six mice of the same age were used as controls. Vaginal smear, TUNEL and hematoxylin-eosin staining were to observe estrous cycles, ovarian cell apoptosis and follicles. Enzyme-linked immunosorbent analysis determined serum estradiol, follicle-stimulating hormone (FSH) and anti-Mullerian hormone (AMH) levels. RT-qPCR and Western Blot analysis were to determine GADD45b, CyclinB1, CDC2 and pCDC2 expressions.; RESULTS: Epirubicin treatment resulted in a decrease in the number of primordial, primary, secondary and antral follicles, an increase in the number of atretic follicles and ovarian cell apoptosis, a decrease in estradiol and AMH levels, an increase in FSH levels, and estrous cycle arrest. However, MB-MSCs combined with BSTCR rescued epirubicin induced POF through down-regulating GADD45b and pCDC2 expressions, and up-regulating CyclinB1 and CDC2 expressions. The combined treatment showed better therapeutic efficacy than BSTCR or MB-MSCs alone.; CONCLUSIONS: MB-MSCs combined with BSTCR improved the ovarian function of epirubicin induced POF mice, which might be related to the inhibition of GADD45b expression and the promotion of CyclinB1 and CDC2 expressions. The combined treatment had better therapeutic efficacy than BSTCR or MB-MSCs alone.

Objectives: To explore the expression and clinical significance of lncRNA-UCA1 in ovarian cancer. Materials and Methods: The expression pf lncRNA-UCA1 in 26 ovarian cancer tissue and 16 normal and benign ovarian tissue were detected using qRT-PCR method, and the correlation of expression level with clinicopathological features were analyzed. Results: Higher lncRNA-UCA1 expression level were detected in ovarian cancer tissue than those in normal ovarian tissue (p<0.05). There were significant correlations between higher expression of lncRNA-UCA1 with tumor staging (p=0.000), histological grades (p=0.000), peritoneal effusion (p=0.001), and lymph node metastasis (p=0.000), but not with age. Conclusion: lncRNA-UCA1 may play a vital role in the metastasis of ovarian cancer and it is expected to be a potential novel biomarker and therapeutic target of ovarian cancer.

临床发现：淋巴瘤等血液疾病的年轻患者应用表柔吡星治疗后出现卵巢早衰。对迫切要求恢复女性生育功能的患者，尚无有效治疗。以干细胞为主体的综合干预是新的研究方向。本课题应用经血子宫内膜间充质干细胞(MB-MMCs)移植联合补肾调冲方(BSTCR)从体外实验和体内试验两部分探讨干预机制。体外实验：应用贴壁法对志愿者的月经血进行分离、提取及鉴定，证实提取的细胞为MB-MMCs。表柔吡星处理后的卵巢颗粒细胞与MB-MMCs共培养后收获颗粒细胞，通过流式细胞学检测凋亡、ELISA检测性激素分泌水平,MB-MMCs能抑制表柔吡星损伤后的人卵巢颗粒细胞的凋亡，改善其性激素的分泌；体内实验：成功构建表柔吡星损伤性卵巢早衰小鼠模型，经尾静脉将ADVLuc标记的MB-MMCs单细胞悬液注射至表柔吡星损伤性小鼠模型，同时BSTCR灌胃，观察小鼠动情周期恢复后处死小鼠，取小鼠血清检测性激素、观察卵巢形态学、TURNEL检测卵巢颗粒细胞凋亡和Westein blot检测小鼠卵巢bcl-2蛋白的表达，发现BSTCR通过促进MB-MMCs的归巢，协同MB-MMCs,促进小鼠卵巢bcl-2蛋白的表达，抑制小鼠卵巢颗粒细胞的凋亡，促进损伤后小鼠卵巢功能的恢复，本研究提示MB-MMCs联合BSTCR可明显的改善表柔吡星所致卵巢早衰小鼠的卵巢功能。

Here we first describe a four-vessel umbilical cord including three umbilical arteries and one vein in a stillbirth. A 28-year-old woman delivered a 2360 g stillbirth in the 33th week of gestation. The infant had no gross anomalies. The placenta was examined pathologically, and the cord was measured as 60.0 cm long, which has four vessels with three arteries and one vein throughout its whole length confirmed by direct and microscopic examination. Fibro-necrosis and dotted necrosis were found in the placenta. A pregnancy with three umbilical arteries may need fetal monitoring during the second trimester. Further observation and adequate investigation are needed in such cases.

目的:比较贴壁法和密度梯度离心法对经血源性子宫内膜间充质干细胞（MB-MSCs）的分离效果。方法:选择25~35岁月经周期正常的健康女性的月经血,分别采用贴壁法和密度梯度离心法分离MB-MSCs并进行传代。镜下观察原代细胞形态变化;对比原代及第2、3代细胞传代时间;流式细胞仪检测表面标志物;阿尔辛兰染色检测其成软骨能力。结果:贴壁法分离的原代细胞呈聚集样生长,密度梯度离心法分离的原代细胞6 d后也呈聚集样生长。贴壁法分离原代细胞的传代时间（14.58±1.31）d明显快于密度梯度离心法（19.17±1.34）d,差异有显著意义（P＜0.05）;第2、3代细胞的传代时间两种分离方法差异无统计学意义（P＞0.05）。经流式细胞仪检测,两种方法分离的MB-MSCs阳性表面标志物CD44、CD29、CD105、CD73含量和阴性表面标志物CD31、CD45含量比较差异无统计学意义（P＞0.05）,两种方法分离的第3代细胞经成软骨诱导后比较无显著差别。结论:采用贴壁法与密度梯度离心法分离MB-MSCs效果相似,但贴壁法更适用于早期快速获得纯度较高的细胞。

Objective. To find a convenient and efficient way to isolate MSCs from human menstrual blood and to investigate their biological characteristics, proliferative capacity, and secretion levels. Methods. MSCs were isolated from menstrual blood of 3 healthy women using adherence. Cell immunological phenotype was examined by flow cytometry; the adipogenic, osteogenic, and chondrogenic differentiation of MSCs was examined by Oil-Red-O staining, ALP staining, and Alcian Blue staining, respectively; and the secretion of cytokines, including vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and insulin-like growth factor-1 (IGF-1), was detected using enzyme-linked immunosorbent assay. Results. MB-MSCs were successfully isolated from human menstrual blood using adherence. They were positive for CD73, CD105, CD29, and CD44, but negative for CD31 and CD45. The differentiated MB-MSCs were positive for ALP staining, Oil-Red-O staining, and Alcian Blue staining. In addition, they could secrete antiapoptotic cytokines, such as VEGF, IGF-1, and HGF. Conclusion. It is feasible to isolate MSCs from human menstrual blood, thus avoiding invasive procedures and ethical controversies. Adherence could be a promising alternative to the density gradient centrifugation for the isolation of MSCs from menstrual blood.

腺垂体功能低下（hypopituitarism）是因腺垂体受损引起相应激素缺乏所致的一种综合征。腺垂体功能低下患者可出现闭经、受孕困难、不孕不育、产后无乳和妊娠并发症,流产、贫血、胎盘早剥、早产和产后出血等发生率较高。腺垂体功能低下患者妊娠前全身充分准备、合理地应用辅助生殖技术,妊娠期和围生期持续监测激素水平,使激素保持在正常水平,可减少妊娠并发症的产生,改善妊娠结局。现综述腺垂体功能低下患者妊娠期准备与围生期处理研究进展。

Hypopituitarism is a disorder characterized by the deficiency of one or more of the hormones secreted by the pituitary gland. Hypopituitarism patients may present the symptoms of amenorrhea, poor pregnancy potential, infertility, and no production of milk after delivery. Successful pregnancy in hypopituitarism patient is rare because hypopituitarism is associated with an increased risk of pregnancy complications, such as abortion, anemia, pregnancy-induced hypertension, placental abruption, premature birth, and postpartum hemorrhage. Hypopituitarism during pregnancy and perinatal period should be managed carefully. The hormone levels should be restored to normal before pregnancy. GH and HMG-hCG are combined to improve follicular growth and the success rate of pregnancy. Hypopituitary patients must be closely monitored as changes may need to be made to their medications, and serial ultrasound measurements are also necessary for fetal growth assessment.